Literature DB >> 6339416

Criteria for the assessment of susceptibility to ceftazidime using the disc diffusion procedure.

H Grimm.   

Abstract

Using regression analyses, we have determined criteria for the assessment of ceftazidime using the agar diffusion test with a 10 micrograms disc. With the ICS procedure, inhibition zones of greater than or equal to 15 mm on Mueller-Hinton agar, greater than or equal to 17 mm on Iso-sensitest agar and greater than or equal to 18 mm on DST agar indicate susceptibility (MIC less than or equal to 16 mg/l). Using the Kirby-Bauer procedure, Mueller-Hinton agar and the same discs, inhibition zones of greater than or equal to 12 mm indicate susceptibility. Minor discrepancies between these results and those found in the literature are due in part to differences in methodology, in particular, however, to differences in the bacteria tested. Mean MIC values for ceftazidime on DST agar were 0.25, 2.83 and 1.0 mg/l, respectively, for the international reference strains Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 25923 and Pseudomonas aeruginosa ATCC 27853.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6339416     DOI: 10.1007/bf01641104

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  7 in total

1.  Ceftazidime regression studies.

Authors:  R Crosse; D G Burt; M J Gardner
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

2.  Bacteriological investigations with ceftazidime in vitro.

Authors:  H Grimm
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

3.  Antibiotic sensitivity testing. Report of an international collaborative study.

Authors:  H M Ericsson; J C Sherris
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1971

4.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

5.  Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.

Authors:  R N Jones; A L Barry; C Thornsberry; E H Gerlach; P C Fuchs; T L Gavan; H M Sommers
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

6.  GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.

Authors:  C H O'Callaghan; P Acred; P B Harper; D M Ryan; S M Kirby; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

7.  Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

  7 in total
  1 in total

1.  [Comparison of the effectiveness of ceftazidime and cefazolin/tobramycin in patients with inflammatory diseases of the lower respiratory tract].

Authors:  N Vetter; H Feist; C Armbruster; M Drlicek
Journal:  Infection       Date:  1987       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.